Drug intelligence / Profile preview

CDCS28

Development stage: Preclinical
Lead developer: Akeso
Modality: Small Molecules

Overview

CDCS28 is an experimental small molecule drug candidate developed by Chipscreen Biosciences for the treatment of obesity and weight loss. Unlike the widely utilized incretin-based therapies, such as GLP-1 receptor agonists, CDCS28 is designed to modulate a non-incretin metabolic pathway to achieve weight reduction. As of early 2024, the specific biological target of the compound has not been publicly disclosed by the developer. The program is currently in the preclinical research stage, representing Chipscreen's expansion into the metabolic disease space beyond its established focus on oncology and diabetes.

Beyond the preview

Go deeper on CDCS28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDCS28.

Explore the full profile